- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03866798
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
January 10, 2024 updated by: Octapharma
Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patrick Murphy
- Phone Number: 866-337-1868
- Email: ctgov@clinicalresearchmgt.com
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Octapharma Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Octapharma Research Site
-
Rochester, Minnesota, United States, 55905
- Octapharma Research Site
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Octapharma Research Site
-
Toledo, Ohio, United States, 43606
- Octapharma Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Octapharma Research Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Octapharma Research Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Octapharma Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Females and males aged from ≥1 year to <18 years old
- Confirmed diagnosis of Chronic Immune Thrombocytopenia (ITP) according to American Society of Hematology (ASH) 2019 guidelines
- Platelets count <30x10^9/L at the Baseline Visit
- Voluntarily given written informed consent (provided by patient's parent or legal guardian) and assent (provided by patient [if age-appropriate per IRB (Institutional Review Board) requirements])
- Sexually active females who have been using at least 1 acceptable form of birth control for a minimum of 30 days (or a minimum of 3 months for hormonal contraceptives) prior to the Screening visit and must agree to use at least 1 acceptable method of contraception throughout the study and for 30 days after the last dose of PANZYGA. Acceptable methods of birth control for this study include: intrauterine device (IUD), hormonal contraception, male or female condom, spermicide gel, diaphragm, sponge, or cervical cap. For non-sexually active females who have begun menstruating, abstinence is considered an acceptable method of birth control.
- Parent or legal guardian must agree and be willing to assist the participant attend study visits, and to follow all protocol requirements and instructions of the study doctor
Exclusion Criteria:
- Thrombocytopenia secondary to other diseases (such as Acquired Immunodeficiency Syndrome [AIDS] or systemic lupus erythematosus [SLE]), drug-related thrombocytopenia, or congenital thrombocytopenia
- Administration of intravenous immunoglobulin (IGIV) or anti-D immunoglobulin within 3 weeks (+/- 3 days) before enrollment
- Administration of thrombopoietin receptor agonists when the dose has NOT been stable within 3 weeks before enrollment and a dosage change is planned before Day 32
- Administration of oral immunosuppressants when the dose has NOT been stable during the preceding 2 months (2 weeks for long-term corticosteroid therapy) and a dosage change is planned before Day 32 (Note: topical agents and inhaled corticosteroid therapy use is permitted)
- Administration of long-term anti-prolific agents or attenuated androgen therapy when the dose has NOT been stable during the preceding 2 months and a dosage change is planned before Day 32
- Nonresponsive to previous treatment with IGIV or anti-D immunoglobulin
- Evidence of an active major bleeding episode at Screening
- Splenectomy in the previous 3 months or planned splenectomy throughout the study period
- Evans syndrome (experiencing active disease with 2 out of 3 of the following: autoimmune thrombocytopenia, autoimmune hemolytic anemia, and/or autoimmune neutropenia)
- Known or suspected human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV) infections
- Emergency surgery in the previous 4 weeks
- Severe liver and/or kidney disease (alanine aminotransferase [ALT] >3x upper limit of normal (ULN), aspartate aminotransferase [AST] >3x upper limit of normal (ULN), and/or creatinine >120 µmol/L)
- History of severe hypersensitivity to blood or plasma derived products, or any component of the PANZYGA
- Known immunoglobulin A (IgA) deficiency and antibodies against IgA
- History of, or suspected alcohol or drug abuse in the previous year
- Females who are pregnant or nursing
- Unable or unwilling to comply with the study protocol
- Receipt of any other investigational medicinal product within 3 months before study entry
- Risk factors* for thromboembolic events in whom the risks outweigh the potential benefit of PANZYGA treatment.
Any other condition(s), that in the Investigator's opinion, make it undesirable for the patient to participate in the study or may interfere with protocol compliance.
- Risk factors include, but are not limited to: obesity, advanced age, hypertension, diabetes, a history of atherosclerosis/vascular disease or thrombotic events, hyperlipidemia, multiple cardiovascular risk factors, acquired or inherited thrombophilic disorders, prolonged periods of immobilization, severe hypovolemia, central venous catheterization, active malignancy and/or known or suspected hyperviscosity.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Panzyga
|
Immune Globulin, intravenous, human-ifas
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Increasing the platelet count in pediatric patients with chronic ITP
Time Frame: 8 Days
|
8 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Reach Platelet Count of at least 50x10^9/L
Time Frame: 32 Days
|
defined as the number of days for subjects to reach Platelet Count of at least 50x10^9/L
|
32 Days
|
Duration of Platelet Response
Time Frame: 32 days
|
defined as the number of days the platelet count remains above at least 50x10^9/L
|
32 days
|
Maximum platelet count recorded during the study
Time Frame: 39 days
|
39 days
|
|
Adverse Events
Time Frame: 39 days
|
Adverse Events
|
39 days
|
Blood Pressure
Time Frame: 39 days
|
Blood Pressure
|
39 days
|
Physical Examinations
Time Frame: 39 days
|
Physical Examinations
|
39 days
|
Heart Rate
Time Frame: 39 days
|
Heart Rate
|
39 days
|
Temperature
Time Frame: 39 days
|
Temperature
|
39 days
|
Respiratory Rate
Time Frame: 39 days
|
Respiratory Rate
|
39 days
|
Complete Blood Count
Time Frame: 39 days
|
Complete Blood Count
|
39 days
|
White Blood Cell Differential
Time Frame: 39 days
|
White Blood Cell Differential
|
39 days
|
Hematocrit
Time Frame: 39 days
|
Hematocrit
|
39 days
|
Hemoglobin
Time Frame: 39 days
|
Hemoglobin
|
39 days
|
Platelet Counts
Time Frame: 39 days
|
Platelet Counts
|
39 days
|
Reticulocytes
Time Frame: 39 days
|
Reticulocytes
|
39 days
|
Bilirubin Levels
Time Frame: 39 days
|
Total, direct, and indirect bilirubin
|
39 days
|
ALT (Alanine Aminotransferase)
Time Frame: 39 days
|
ALT
|
39 days
|
AST (Aspartate Aminotransferase)
Time Frame: 39 days
|
AST
|
39 days
|
Creatinine
Time Frame: 39 days
|
Creatinine
|
39 days
|
Sodium
Time Frame: 39 days
|
Sodium
|
39 days
|
Calcium
Time Frame: 39 days
|
Calcium
|
39 days
|
Potassium
Time Frame: 39 days
|
Potassium
|
39 days
|
BUN (blood urea nitrogen)
Time Frame: 39 days
|
BUN
|
39 days
|
LDH (lactase dehydrogenase)
Time Frame: 39 days
|
LDH
|
39 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 21, 2020
Primary Completion (Estimated)
April 1, 2024
Study Completion (Estimated)
April 1, 2024
Study Registration Dates
First Submitted
March 6, 2019
First Submitted That Met QC Criteria
March 6, 2019
First Posted (Actual)
March 7, 2019
Study Record Updates
Last Update Posted (Actual)
January 11, 2024
Last Update Submitted That Met QC Criteria
January 10, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
Other Study ID Numbers
- NGAM-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Immune Thrombocytopenia
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingChronic Primary Immune Thrombocytopenia (ITP)China
-
Hadassah Medical OrganizationTerminatedChildhood Chronic Immune ThrombocytopeniaIsrael
-
Gruppo Italiano Malattie EMatologiche dell'AdultoNot yet recruitingITP - Immune Thrombocytopenia | Chronic ITP | Refractory ITP
-
Eisai Inc.CompletedImmune Thrombocytopenia | Chronic ThrombocytopeniaPoland, Ukraine, Belgium, Bulgaria, South Africa, Netherlands, New Zealand, Singapore, Australia, Slovakia, Czechia
-
Ramsay Générale de SantéEuropean Clinical Trial Experts NetworkNot yet recruitingChronic Renal Failure | Heparin-induced Thrombocytopenia | Dialysis; ComplicationsFrance
-
Institute of Hematology & Blood Diseases HospitalNovartis; The Second Hospital of Hebei Medical University; Henan Cancer Hospital and other collaboratorsCompletedChronic HBV Infection | Thrombocytopenia PurpuraChina
-
Institute of Hematology & Blood Diseases Hospital...Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaboratorsRecruitingPrimary Immune Thrombocytopenia (ITP)China
-
argenxWithdrawnPrimary Immune Thrombocytopenia (ITP)
Clinical Trials on Panzyga
-
OctapharmaRecruitingPediatric Acute-Onset Neuropsychiatric SyndromeUnited States, Sweden, Italy
-
Henry Ford Health SystemOctapharma USA, Inc.RecruitingSmall Fiber Neuropathy | Autoimmune Small Fiber Neuropathy | Inflammatory Polyneuropathy | Immune-Mediated NeuropathyUnited States
-
OctapharmaRecruitingChronic Lymphocytic Leukemia | HypogammaglobulinemiaUnited States, Denmark, Germany, Hungary, Italy, Poland, Russian Federation, Spain, Czechia, Greece, Israel, Turkey
-
OctapharmaRecruitingPediatric Chronic Inflammatory Demyelinating PolyneuropathyUnited States
-
OctapharmaCompletedChronic Inflammatory Demyelinating Poly(Radiculo)NeuropathyCanada, Poland, Romania, Ukraine, Bulgaria, Czechia, Germany, Hungary, Russian Federation
-
OctapharmaCompletedPrimary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIGCanada, Austria, France, Spain, United Kingdom
-
Vera BrilUnknownChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLocalized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia